Congrats Moritz Reike and Decipher by Veracyte Ewan Gibb for putting light on baseline features of patients relapsing after neoadjuvant Pembro and RC in #MIBC #PURE01 ASCO UroToday.com

What an inspiring journey by super star ⁦⁦Brigham and Women's Hospital Department of Urology⁩ leader ⁦Quoc-Dien Trinh, MD, MBA⁩ tackling Health Disparities in prostate cancer! Hats off Quoc! ⁦Brigham and Women's Hospital⁩ ⁦Dana-Farber⁩ ⁦Harvard Medical School⁩ ⁦Dana-Farber Lank Center for Genitourinary Oncology⁩ bwhclinicalandresearchnews.org/2023/05/12/tri…

Is there any differences between BCG unresponsive relapsing & refractory NMIBC? We investigated this using our MD Anderson Cancer Center BCG unresponsive NMIBC cohort treated with bladder sparing treatments in BJU International tinyurl.com/ms4eye2r

Modified Glasgow Prognostic Score for Metastatic Renal Cell Carcinoma 🔍Prognostic and predictive effect of CRP plus albumin It can be used as a tumor marker in RCC👇 JAMA Oncology OncoAlert jamanetwork.com/journals/jamao…

CheckMate901 is positive👏Awesome news for metastatic UC pts!!!! First time anything beats CISGEM for OS in all patients!!! Hopefully EV302 will come next. Why KN361 & IM130 were not consistent? ⁦OncoAlert⁩ ⁦GUARD Consortium⁩ ⁦UroToday.com⁩ investors.bms.com/iframes/press-…

🔘Promising results for bladder-sparing treatment in node-positive bladder cancer! 🔘Equivalent survival outcomes with surgery or radical radiotherapy. 🔘Empower patients in their decision-making for better outcomes. Journal of Clinical Oncology Prof Ananya💙 @achoud72.bsky.social ASTRO European Association of Urology (EAU) Amer. Urol. Assn.

Un percorso per i nostri pazienti associazionepalinuro , per facilitare l’accesso a cure seguendo le linee guida European Association of Urology (EAU) #instillazione #robotica #eras #mdt EAU YAU Urothelial Carcinoma

Check out our paper BJU International: -> no oncologic benefit to extended PLND at RC in cN+ BCa regardless of periop chemo ~ 30% distant Mx ~ 13% locoregional rec ⛔️ cN+ is associated with a significant staging bias Thanks to Benjamin Pradere and Shahrokh F. Shariat doi.org/10.1111/bju.16…

💥 Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer jnj.com/johnson-johnso…

T-DXd with 56.3% ORR in HER2 IHC 3+ met. UC 🎯 Important validation that ADC efficacy depends on target gene expression. Same applies to other heterogeneously ADC targets like NECTIN4. Big step towards 1st tumor agnostic ADC approval UroToday.com Markus Eckstein Viktor Grünwald

One of the most important messages during #eau24. PRIME study. No need for contrast enhancement during MRI for patients with elevated PSA.

Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…

🚨 Exciting Update! 🚨 Our new EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pembro combo in #metastaticurothelialcarcinoma has just been published in European Urology!!!! This breakthrough could significantly reshape daily clinical practice!

The Publish or Perish Game is a humorous party game about academic publishing. Players race to publish manuscripts with useless nonsense while sabotaging each other's research and delivering "very helpful" comments, Reviewer 2 style.

Vincent Hoffman zur Fast Track Steintherapie der Herner FAST 6 Studie 💪🏼💪🏼 #DGU24 RUB Urology DGU Kongress GeSRU

Full House für Dr. Peter Bach von RUB Urology zur Anwendung von DJ Schienen im klinischen Alltag #DGU24 DGU Kongress BvDUrologie

🚀Finally, Urology: Unboxed is fully published in our App! You can now pre-order the physical book. Made for first-year urology residents—it would be a great gift! If you're interested or know someone starting their journey, share this link: knowuro.com/books/unboxed/

Super important paper on T-DXd resistance in breast cancer: acquired resistance often driven by ↓HER2 expression. Yet another study highlighting that ADC target expression matters! We urgently need similar studies in mUC—especially as ADC sequencing is on the horizon! For